Dr. Jing Fan, a Canadian citizen, received her bachelor’s degree at Peking University, Ph.D in Neuroscience at UBC, and postdoctoral training at ICE, Johns Hopkins University. She has been elected as one of the 2022 Forbes list “TOP50 Women in Science and Technology in China”, the "outstanding founder in biotechnology industry of 2022"BioCon Award, etc. Dr. Jing Fan has more than 20 years of experience in the fields of pluripotent stem cell and neural differentiation, CNS diseases drug discovery. She has published more than 10 academic papers and book chapters on top journals and led the Maryland Stem Cell Fundation project, and participated in major R&D projects such as NIH, Helis Foundation, etc. Since 2017, she has founded Hopstem, and led the team to establish advanced CMC and development platform for iPSC-derived cell therapy products and raised more than 70 million USD funding from VCs. The company has developed several product pipelines targeting CNS unmet medical needs, including the recent IND approved by FDA of hNPC01 targeting chronic ischemic stroke.